ПРОФИЛАКТИКА ПНЕВМОКОККОВОЙ ИНФЕКЦИИ У ДЕТЕЙ – ПОЛОЖИТЕЛЬНОЕ ВЛИЯНИЕ НА ПОПУЛЯЦИЮ В ЦЕЛОМ
Аннотация
Ключевые слова: дети, пневмококковая инфекция, вакцинация
(Вопросы современной педиатрии. 2008;7(6):66-71)
Список литературы
1. WHO Global Immunization Vision and Strategy. Доступно на: www.who.int/vaccines/GIVS/english/Global_imm._data_EN.pdf.
2. UNICEF. Pneumonia the forgotten killer of children. Доступно на: www.unicef.org/publications/files/Pneumonia_The_Forgotten_Killer_of_Children.pdf.
3. Пневмококковая инфекция респираторной системы в детском возрасте. Практическое руководство для врачей. Под ред. Н.А. Геппе, А.Б Малахова. М. 2005.
4. Катосова Л.К. Этиология пневмоний. В кн.: Острые пневмонии у детей. Под ред. В.К. Таточенко. Чебоксары: Чувашский университет. 1994.
5. Weekly Epidemiological Record. 2007. №12, № 82. Р. 93–104. Доступно на: www.who.int/wer
6. Pneumococcal vaccines the impact of conjugate vaccine. Ed. by G.R. Siber, K.P. Klugman, P.H. Makela. NY: ASM Press. 2008. Р. 450.
7. Eskola J., Kilpi T., Palmu A. et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N. Engl. J. Med. 2001; 344 (6): 403–409.
8. Black S., Shinefield H., Ling S. et al Effectiveness of heptavalent-pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatrics Infect. Dis. J. 2002; 21 (9): 810–815.
9. Black S., Shinefield H., Fireman B. et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatrics Infect. Dis. J. 2000; 19 (3): 187–195.
10. Centers for Disease Control and Prevention. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease, United States, 1998-2003. MMWR. 2005; 54 (36): 893–897.
11. Centers for Disease Control and Prevention. Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction, 1998–2005. MMWR. 2008; 57 (6): 141–168.
12. Centers for Disease Control and Prevention, National Immunization Program, Record of the Advisory Committee on Immunization Practices. October 15-16 2003. Доступно на: www.cdc.gov/nip/ACIP/minutes.htm
13. Black S., Shinefield H., Baxter R. et al. Postlicensure surveillance for pneumococcal invasive disease after use of heptavalent pneumococcal conjugate vaccine in Northern California Kaiser Permanente. Pediatrics Infect. Dis. J. 2004; 23 (6): 485–489.
14. Poehling K.A., Talbot T.R., Griffin M.R. et al. Invasive pneumococcal disease among young infants before and after pneumococcal conjugate vaccine introduction. JAMA. 2006; 295 (14): 1668–1674.
15. Stephens D.S., Zughaier S.M., Whitney C.G. et al. Incidence of macrolide resistance in Streptococcus pneumoniae after introduction of the pneumococcal conjugate vaccine: population-based assessment. Lancet. 2005; 365 (9462): 855–863.
Для цитирования:
Федосеенко М. ПРОФИЛАКТИКА ПНЕВМОКОККОВОЙ ИНФЕКЦИИ У ДЕТЕЙ – ПОЛОЖИТЕЛЬНОЕ ВЛИЯНИЕ НА ПОПУЛЯЦИЮ В ЦЕЛОМ. Вопросы современной педиатрии. 2008;7(6):66-71.
For citation:
Fedoseenko M. PROPHYLAXIS OF PNEUMOCOCCAL INFECTION IN CHILDREN HAS POSITIVE EFFECT ON ALL POPULATION. Current Pediatrics. 2008;7(6):66-71. (In Russ.)
Послать статью по эл. почте 